Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

Also called NCT04820907

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04820907
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04820907. Randomized; double masking; primary purpose treatment. Start 2020-10-27 (actual); primary completion 2021-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
Condition
Hypertension
Intervention (Drug)
HCP1904-1
Intervention (Drug)
RLD2001-1
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct04820907
Content hash
0723ac865ae46eccc91a3511206c7782dff888a43aa703bbbacf960332c1d160